Arecor Therapeutics plc

AREC

GB00BMWLM973

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 03:07:10 2024-04-24 am EDT			5-day change	1st Jan Change
133 ^GBX	+0.38%		+3.50%	-27.12%

Apr. 23	Arecor chief financial officer to leave in July after five years	AN
Apr. 23	Arecor Therapeutics CFO to Leave in July	MT

Arecor Therapeutics plc Appoints Lindsey Foulkes as Chief Operating Officer

June 10, 2021 at 02:00 am EDT

Arecor Therapeutics plc announced the appointment of Dr. Lindsey Foulkes as the Company's Chief Operating Officer.

Latest news about Arecor Therapeutics plc

Arecor chief financial officer to leave in July after five years	Apr. 23	AN
Arecor Therapeutics CFO to Leave in July	Apr. 23	MT
Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Chief Financial Officer, Effective from July 22, 2024	Apr. 23	CI
Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Company Secretary and as A Board Director, Effective from July 22,2024	Apr. 23	CI
Arecor to develop "holy grail" diabetes treatment with partner TRx	Mar. 12	AN
Arecor Therapeutics plc and Trx Biosciences Limited Announces Research Collaboration for the Formulation Development of an Oral GLP-1 Receptor Agonist Product	Mar. 12	CI
EARNINGS AND TRADING: East Star, Getech strike Kazakhstan JV	Feb. 29	AN
Arecor Therapeutics hails Arestat as 2023 performance "strong"	Feb. 01	AN
Arecor pleased as investee Inhibrx sells therapy to Sanofi	Jan. 23	AN
Patent boosts for DG Innovate and Arecor Therapeutics	Jan. 18	AN
Arecor Therapeutics Gains European Patent for Insulin Product Formulations	Jan. 18	MT
Arecor expands speciality hospital collaboration with partner	Jan. 08	AN
Arecor Therapeutics Expands Formulation Study Collaboration with Pharmaceutical Partner	Jan. 08	MT
Arecor Therapeutics plc Expands Ongoing, Exclusive Formulation Study Collaboration with the Pharmaceutical Division of One of the World's Largest Chemicals Marketing and Pharmaceuticals Companies	Jan. 08	CI
Arecor inks co-development deal with global medical company	Dec. 04	AN
Arecor Therapeutics Signs Exclusive License Option Agreement for Oncology Product	Dec. 04	MT
Arecor Therapeutics plc Announces Co-Development and Exclusive Licence Option Agreement	Dec. 04	CI
Arecor inks Eli Lilly deal; RBG appoints McNair CFO	Nov. 29	AN
Arecor Therapeutics Signs Further Collaboration With Eli Lilly	Nov. 29	MT
Arecor Therapeutics plc Signs Further Collaboration Agreement with Lilly and Company	Nov. 29	CI
Arecor Therapeutics gets "milestone payment" from AT220 sale	Nov. 17	AN
Arecor Therapeutics to Receive Milestone Payment from Maiden Commercial Sale of Arestat Technology Product	Nov. 17	MT
Troy Income suspends buyback of shares	Nov. 02	AN
Arecor Therapeutics to Receive Milestone Payment from Inhibrx	Nov. 02	MT
Arecor Therapeutics ups subject numbers for insulin-focused trial	23-10-02	AN

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Arecor Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.325 GBP

Average target price

4.71 GBP

Spread / Average Target

+255.47%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARECOR THERAPEUTICS PLC	-27.12%	50.48M
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+48.04%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research